Zobrazeno 1 - 10
of 155
pro vyhledávání: '"Marc Espié"'
Autor:
Gaëlle Douchet, Marc Espié
Publikováno v:
Soins. 64:56-59
Le traitement medical des cancers du sein s'est considerablement enrichi ces dernieres annees z Les indications therapeutiques ont ete affinees grâce a la classification moleculaire des cancers. La chimiotherapie restera encore pour quelques annees
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 19(8)
Autor:
Mailliez A, Charles Coutant, Marc Espié, Berkach C, Maitrot L, Fabien Reyal, Giacchetti S, Decanter C, Lucie Laot, Julien Guerin, C Sautter, Aullene Toussaint, Sablone L, Julie Labrosse, Rousset C, Enora Laas, Plu-Bureau G, P Santulli, Fumoleau P, Clara Sebbag, Ines Abdennebi, Anne-Sophie Hamy, Jacot W, Elise Dumas, Nadir Sella, Khallouch S, Bernard Asselain, Bobrie A, Manon Mangiardi-Veltin, Wang Y, Ray-Coquard I, Chapron C, Senechal-Davin C, Delrieu L, Manuel Rodrigues, Florence Coussy
ObjectiveTo study fertility concerns and oncofertility practices at time of breast cancer (BC) diagnosis.DesignThe FEERIC study (Fertility, Pregnancy, Contraception after BC in France) is a prospective, multicenter study.SettingWeb-based collaborativ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a1f453deef6f5faa90691b53d80cfcb
https://doi.org/10.1101/2021.06.07.21258472
https://doi.org/10.1101/2021.06.07.21258472
Autor:
Michel Marty, Marc Espié, Barbara Pistilli, Sylvie Giacchetti, Junheng Gao, Enora Laas, Sandrine Tury, F Reyal, Brice Aouchiche, Jean-Yves Pierga, E. Brain, Martin J. Edelman, Bernard Asselain, Gabriel Benchimol, Marick Laé, Xiaofei Wang, Anne-Sophie Hamy
Publikováno v:
Journal of Clinical Oncology. 37:624-635
PURPOSE The overexpression of cyclooxygenase 2 (COX-2) gene, also known as prostaglandin-endoperoxide synthase 2 ( PTGS2), occurs in breast cancer, but whether it affects response to anticox drugs remains unclear. We investigated the relationships be
Autor:
F-C Bidard, C. Simondi, Delphine Loirat, Frédérique Berger, Véronique Diéras, J-Y Pierga, PH Cottu, William Jacot, J-M Ferrero, Thomas Bachelot, Marc Espié, Catherine Alix-Panabières, Sylvain Ladoire, Sylvain Dureau, C. Levy, H Bourgeois, Florence Dalenc, Joseph Gligorov, A. Gonçalves, E. Brain, H. Naman
Publikováno v:
Cancer Research. 79:GS3-07
Background: In ER+ HER2- metastatic breast cancer (MBC) patients, the clinical choice between 1st line hormone therapy (HT, the recommended option) or chemotherapy (CT) is based on the absence of “visceral crisis” or adverse prognostic factors, w
Autor:
Florence Ledoux, A de Roquancourt, Stéphanie Bécourt, Paul Blanc-Durand, A. Binasker, Luca Campedel, Caroline Cuvier, Sylvie Giacchetti, L. Teixeira, Marc Espié, C Gardnair
Publikováno v:
Cancer Research. 79:P5-17
Background Inflammatory breast cancers (IBC) particularly triple negative (TN) subtype have poor prognosis. There are few series reporting IBC outcome according to their immunohistochemical profile. We have already shown the efficiency of dose dense
Autor:
Stéphanie Catala, Laetitia Gambotti, C. Faure Mercier, L. Venat-Bouvet, Xavier Pivot, Sophie Paget-Bailly, Iris Pauporté, J-M Grouin, Christelle Jouannaud, J-Y Pierga, Julie Henriques, Maria Rios, David Khayat, Gilles Romieu, P. Kerbrat, Thomas Bachelot, P. Fumoleau, Daniel Serin, Marc Espié, Marc Debled, Sophie Abadie-Lacourtoisie, J.P. Jacquin, Alain Lortholary, L. Cany
Publikováno v:
Cancer Research. 79:GS2-07
Since 2005, 12 months of trastuzumab added to chemotherapy alone is the standard of care in patients with HER2-positive breast cancer. PHARE ('Protocol for Herceptin® as Adjuvant therapy with Reduced Exposure') is the first trial comparing a reducti
Autor:
S.ophie Guillerm, Caroline Cuvier, Eva Marchand, Laurent Quero, Marc Espié, E. Bourstyn, Henri Lorphelin, Luis Augusto Teixeira, Ramona Itti, Sylvie Giacchetti, Laurence Cahen-Doidy, Christophe Hennequin, Mouna Labidi
Publikováno v:
Clinical breast cancer. 22(1)
Purpose To evaluate outcomes and post-operative toxicities after intra-operative radiotherapy (IORT) in elderly women Population Women older than 65 years, with an infiltrating ductal breast cancer ≤3 cm, expressing Estrogen receptors (ER+) without
Autor:
Jean-Yves Pierga, V. Servent, Véronique D'Hondt, Hugues Bourgeois, Véronique Diéras, William Jacot, Laurence Venat-Bouvet, Marie-Paule Sablin, Elisabeth Luporsi, Séverine Guiu, François-Clément Bidard, Frédérique Berger, Etienne Brain, Marc A. Bollet, Marc Espié, Alain Lortholary, Souhir Neffati, Coraline Dubot, Paul Cottu
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
BackgroundIn this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC.MethodsMain inclusion criteria for screening were as follows: women
Autor:
Philippe Bertheau, Lucie Biard, Brigitte Poirot, Christos Sotiriou, Luis Augusto Teixeira, Jacqueline Lehmann-Che, Matthieu Resche-Rigon, Patricia de Cremoux, Pascal Merlet, Fatiha Bouhidel, David Groheux, Marc Espié
Publikováno v:
Oncotarget
Oncotarget, 9 (23
Oncotarget, 9 (23
Background: The efficacy of neoadjuvant chemotherapy regimens in advanced luminal breast cancer patients is difficult to predict. Intrinsic properties of breast tumors, including altered gene expression profile and dynamic evaluation of metabolic pro